<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635739</url>
  </required_header>
  <id_info>
    <org_study_id>1493</org_study_id>
    <nct_id>NCT00635739</nct_id>
  </id_info>
  <brief_title>Effect of Whey Protein Supplementation and Resistance Exercise on Muscle Parameters in Older Adults</brief_title>
  <official_title>Efficacy of Whey Protein Supplementation on Resistance Exercise-Induced Changes in Muscle Strength, Fat Free Mass, and Function in Mobility-Limited Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Dairy Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is looking at the effects of a whey protein nutritional supplement on
      changes in muscle mass, strength and physical function in response to a 6 month program of
      strength training exercise.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 Repetition Maximum Muscle Strength 1-RM (N) Double Leg Press</measure>
    <time_frame>Baseline and follow up (6 months)</time_frame>
    <description>The maximum muscle strength of the leg extensor muscles as measured by pneumatic strength training equipment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lean Mass</measure>
    <time_frame>Baseline and follow up (6 months)</time_frame>
    <description>Whole body lean mass (kg) as measured by dual energy x-ray absorptiometry.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Mobility Limitation</condition>
  <arm_group>
    <arm_group_label>A, 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A, 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whey protein</intervention_name>
    <description>powdered, 46g supplement dissolved in fluids, twice daily</description>
    <arm_group_label>A, 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin placebo</intervention_name>
    <description>powdered, 46g supplement dissolved in fluids, twice daily</description>
    <arm_group_label>A, 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Females 70-85 yrs

          -  Community dwelling

          -  Short Physical Performance Battery score &lt; 10

          -  BMI = 21-32.5

        Exclusion Criteria:

          -  Acute or terminal illness

          -  Mini Mental State Exam &lt; 23

          -  Myocardial infarction in previous 6 months, symptomatic coronary artery disease, or
             congestive heart failure

          -  Upper or lower extremity fracture in previous 6 months

          -  Uncontrolled hypertension (&gt;150/90 mm Hg).

          -  Neuromuscular diseases and drugs which affect neuromuscular function.

          -  Hormone replacement therapy

          -  eGFR &lt;30 mL/min/1.73m2

          -  Types I and II Diabetes Mellitus

          -  Dietary protein intake &lt; 0.8 g.kg-1.day-1

          -  Disorders of nutrient absorption

          -  Milk, or whey allergy

          -  Sulfa drugs and allergy to PABA-containing sunscreens
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger A Fielding, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jean Mayer USDA Human Nutrition Research Center on Aging</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Mayer USDA Human Nutrition Research Center on Aging</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>March 7, 2008</study_first_submitted>
  <study_first_submitted_qc>March 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <results_first_submitted>May 26, 2017</results_first_submitted>
  <results_first_submitted_qc>December 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 18, 2019</results_first_posted>
  <last_update_submitted>December 4, 2018</last_update_submitted>
  <last_update_submitted_qc>December 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tufts University</investigator_affiliation>
    <investigator_full_name>Roger A Fielding</investigator_full_name>
    <investigator_title>Director and Senior Scientist, Professor of Nutrition, Jean Mayer USDA Human Nutrition Research Center on Aging.</investigator_title>
  </responsible_party>
  <keyword>Whey protein</keyword>
  <keyword>Resistance exercise</keyword>
  <keyword>Physical activity</keyword>
  <keyword>Mobility disability</keyword>
  <keyword>Physical function</keyword>
  <keyword>Muscle mass</keyword>
  <keyword>Muscle strength</keyword>
  <keyword>Older Adults</keyword>
  <keyword>Mobility-Limited</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mobility Limitation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Whey Protein</title>
          <description>Whey protein: powdered, 46g supplement dissolved in fluids, twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Maltodextrin placebo: powdered, 46g supplement dissolved in fluids, twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A,1 (Intervention)</title>
          <description>Whey protein: powdered, 46g supplement dissolved in fluids, twice daily</description>
        </group>
        <group group_id="B2">
          <title>A,2 (Control)</title>
          <description>Maltodextrin placebo: powdered, 46g supplement dissolved in fluids, twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.0" spread="4.0"/>
                    <measurement group_id="B2" value="77.3" spread="3.9"/>
                    <measurement group_id="B3" value="77.7" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1 Repetition Maximum Muscle Strength 1-RM (N) Double Leg Press</title>
        <description>The maximum muscle strength of the leg extensor muscles as measured by pneumatic strength training equipment.</description>
        <time_frame>Baseline and follow up (6 months)</time_frame>
        <population>5 subjects were not included in follow up analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Whey Protein</title>
            <description>Whey protein: powdered, 46g supplement dissolved in fluids, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Maltodextrin placebo: powdered, 46g supplement dissolved in fluids, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>1 Repetition Maximum Muscle Strength 1-RM (N) Double Leg Press</title>
          <description>The maximum muscle strength of the leg extensor muscles as measured by pneumatic strength training equipment.</description>
          <population>5 subjects were not included in follow up analysis</population>
          <units>N</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1223" spread="380"/>
                    <measurement group_id="O2" value="1256" spread="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1483" spread="517"/>
                    <measurement group_id="O2" value="1465" spread="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lean Mass</title>
        <description>Whole body lean mass (kg) as measured by dual energy x-ray absorptiometry.</description>
        <time_frame>Baseline and follow up (6 months)</time_frame>
        <population>5 subjects were not included in follow up analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Whey Protein</title>
            <description>Whey protein: powdered, 46g supplement dissolved in fluids, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Maltodextrin placebo: powdered, 46g supplement dissolved in fluids, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Lean Mass</title>
          <description>Whole body lean mass (kg) as measured by dual energy x-ray absorptiometry.</description>
          <population>5 subjects were not included in follow up analysis</population>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" spread="8.6"/>
                    <measurement group_id="O2" value="46.4" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="8.6"/>
                    <measurement group_id="O2" value="46.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Whey Protein</title>
          <description>Whey protein: powdered, 46g supplement dissolved in fluids, twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Maltodextrin placebo: powdered, 46g supplement dissolved in fluids, twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>hospitalization</sub_title>
                <description>Hospitalization reason is not know.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI distress</sub_title>
                <description>GI upset</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Laboratory</sub_title>
                <description>Abnormal laboratory value</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Illness</sub_title>
                <description>Illness that would restrict physical activity</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <description>Non-injurious fall</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <description>Musculoskeletal pain/injury</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery</sub_title>
                <description>Outpatient surgical procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Roger Fielding</name_or_title>
      <organization>Tufts University</organization>
      <phone>6175563083</phone>
      <email>Roger.Fielding@tufts.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

